주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요새 탭/창에서 열기

Elsevier
엘스비어와 함께 출판
Press release

Eating More Fruits & Vegetables to Reduce Dietary Acid Lowers Blood Pressure and Improves Kidney and Heart Health in Patients with Hypertension

2024년 8월 6일

Findings from a five-year interventional randomized control trial of patients with hypertension in The American Journal of Medicine provides further evidence of the benefits of fruit and vegetable consumption

Doctors recommend making fruits and vegetables a foundational part of the treatment of patients with hypertension. Diets high in fruits and vegetables are found to lower blood pressure, reduce cardiovascular risk, and improve kidney health due to their base-producing effects. A new studyopens in new tab/window in The American Journal of Medicineopens in new tab/window, published by Elsevier, details the findings from a five-year interventional randomized control trial.

Despite ongoing efforts to improve hypertension treatment and reduce its adverse outcomes with pharmacological strategies, hypertension-related chronic kidney disease and its cardiovascular mortality are increasing. Heart disease is the number one reason that patients with chronic kidney disease die.

The Dietary Approaches to Stop Hypertension (DASH) diet that is rich in fruits and vegetables reduces blood pressure and is the recommended first-line treatment for primary hypertension. Nevertheless, this diet is under-prescribed, and when prescribed is under-implemented despite supportive epidemiological data. The DASH diet and others generally high in fruits and vegetables are associated with lower blood pressure, lower risk for and progression of chronic kidney disease, lower cardiovascular disease risk indicators, and lower cardiovascular disease mortality.

Lead investigator of the study Donald E. Wesson, MD, MBA, Department of Internal Medicine, Dell Medical School – The University of Texas at Austin, says, "As a nephrologist (kidney doctor), my acid-base laboratory studies ways by which the kidney removes acid from the blood and puts it into the urine. Our animal studies showed years ago that mechanisms used by kidneys to remove acid from the blood can cause kidney injury if the animals were chronically (long term) exposed to an acid-producing diet. Our patient studies showed similar findings: that is, an acid-producing diet (one high in animal products) was kidney-harmful, and one that is base-producing (one high in fruits and vegetables) is kidney-healthy. Other investigators showed that a diet high in fruits and vegetables is heart-healthy. We hypothesized that one way that fruits and vegetables are both kidney- and heart-healthy is that they reduce the amount of acid in the diet and therefore the amount of acid that kidneys have to remove from the body."

To test this hypothesis, a study was designed in which participants with hypertension, but not diabetes, and very high levels of urine albumin excretion (macroalbuminuria) were selected. Patients with macroalbuminuria have chronic kidney disease, a high risk for the worsening of their kidney disease with time, and a high risk to subsequently develop cardiovascular diseases. In a randomized control trial over a five-year period, investigators divided the cohort of 153 patients with hypertension into three groups:

Study participants adding 2-4 cups of base-producing fruits and vegetables in addition to their usual daily food intake

Study participants prescribed NaHCO3 (acid-reducing sodium bicarbonate, which is common baking soda) tablets in two daily doses of 4-5 650 mg tablets

Study participants receiving standard medical care from primary care clinicians.

The results of the study show that both fruits and vegetables and NaHCO3 improved kidney health, but only fruits and vegetables, and not NaHCO3, reduced blood pressure and improved indices of cardiovascular disease risk.

Co-investigator Maninder Kahlon, PhD, Department of Population Health, Dell Medical School – The University of Texas at Austin, explains, "Importantly, fruits and vegetables achieved the latter two benefits with lower doses of medication used to lower blood pressure and reduce cardiovascular disease risk. This means that one can get the kidney health benefits with either fruits and vegetables or NaHCO3, but we get the blood pressure reduction and reduced cardiovascular disease risk with fruits and vegetables, but not with NaHCO3. This supports our recommendation that fruits and vegetables should be ‘foundational’ treatment for patients with hypertension, because we accomplish all three goals (kidney health, lower blood pressure, and reduced cardiovascular disease risk) with fruits and vegetables, and we can do so with lower medication doses.

The research team emphasizes "foundational" because many clinicians begin hypertension treatment with drugs and then add diet strategies if blood pressure is not properly controlled. The findings from its studies support the opposite: treatment should begin with fruits and vegetables and then add drugs as needed.

Dr. Wesson concludes, "Dietary interventions for chronic disease management are often not recommended and even less often executed because of the many challenges to get patients to implement them. Nevertheless, they are effective, and in this instance, kidney and cardiovascular protective. We must increase our efforts to incorporate them into patient management and more broadly, make healthy diets more accessible to populations at increased risk for kidney and cardiovascular disease.”

The researchers also advise patients with hypertension to ask their clinician to measure a urine albumin-to-creatinine ratio (UACR) to determine if they have underlying kidney disease and an increased risk for subsequent cardiovascular disease.

Notes for editors

The article is “Kidney and Cardiovascular Protection Using Dietary Acid Reduction in Primary Hypertension: A Five-Year, Interventional, Randomized, Control Trial,” by Nimrit Goraya, MD, Nicolaos E. Madias, MD, Jan Simoni, PhD, DVM, Maninder Kahlon, PhD, Nazan Aksan, PhD, and Donald E. Wesson, MD, MBA (https://doi.org/10.1016/j.amjmed.2024.06.006opens in new tab/window). It appears online in advance of The American Journal of Medicine, volume 137, issue 11 (November 2024), published by Elsevier and is openly available for 30 days.

Full text of the article is also available to credentialed journalists upon request. Contact Melissa Ramondetta at +1 406 542 8397 or [email protected]opens in new tab/window to request the PDF or additional information. Journalists who would like to interview the authors should contact Shahreen Abedin. JD, Director of Media Relations, Communications, Dell Medical School – The University of Texas at Austin at +1 347 419-2657 or [email protected]opens in new tab/window.

These studies were supported by the Larry and Jane Woirhaye Memorial Endowment in Renal Research at the Texas Tech University Health Sciences Center, funds from the University Medical Center (Lubbock, TX) Endowment, Academic Operations Division of Baylor Scott & White Health, and the Episcopal Health Foundation.

About The American Journal of Medicine

The American Journal of Medicineopens in new tab/window (AJM), known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. The official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus US medical schools, AJM publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. www.amjmed.comopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.

연락처

MR

Melissa Ramondetta

Publisher

Elsevier

+1 406 542 8397

Melissa Ramondetta 이메일